Blinatumomab Safe, Efficacious for Infants With KMT2A-Rearranged Leukemia

THURSDAY, April 27, 2023 -- For infants younger than 1 year of age with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia (ALL), a bispecific T-cell engager molecule targeting CD19, blinatumomab, is safe and has a high level of efficacy,...